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Berberine)
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Greater Manchester, United Kingdom
Elevated mitochondrial biogenesis and/or metabolism are distinguishing features of
cancer cells, as well as Cancer Stem Cells (CSCs), which are involved in tumor initiation,
metastatic dissemination, and therapy resistance. In fact, mitochondria-impairing agents
can be used to hamper CSCs maintenance and propagation, toward better control
of neoplastic disease. Tri-Phenyl-Phosphonium (TPP)-based mitochondrially-targeted
compounds are small non-toxic and biologically active molecules that are delivered
to and accumulated within the mitochondria of living cells. Therefore, TPP-derivatives
may represent potentially “powerful” candidates to block CSCs. Here, we evaluate
the metabolic and biological effects induced by the TPP-derivative, termed Dodecyl-
TPP (d-TPP) on breast cancer cells. By employing the 3D mammosphere assay in
MCF-7 cells, we demonstrate that treatment with d-TPP dose-dependently inhibits the
propagation of breast CSCs in suspension. Also, d-TPP targets adherent “bulk” cancer
cells, by decreasing MCF-7 cell viability. The analysis of metabolic flux using Seahorse
Xfe96 revealed that d-TPP potently inhibits the mitochondrial oxygen consumption rate
(OCR), while simultaneously shifting cell metabolism toward glycolysis. Thereafter, we
exploited this ATP depletion phenotype and strict metabolic dependency on glycolysis to
eradicate the residual glycolytic CSC population, by using additional metabolic stressors.
More specifically, we applied a combination strategy based on treatment with d-TPP, in
the presence of a selected panel of natural and synthetic compounds, some of which are
FDA-approved, that are known to behave as glycolysis (Vitamin C, 2-Deoxy-Glucose) and
OXPHOS (Doxycyline, Niclosamide, Berberine) inhibitors. This two-hit scheme effectively
decreased CSC propagation, at concentrations of d-TPP toxic only for cancer cells,
but not for normal cells, as evidenced using normal human fibroblasts (hTERT-BJ1) as
a reference point. Taken together, d-TPP halts CSCs propagation and targets “bulk”
cancer cells, without eliciting the relevant undesirable off-target effects in normal cells.
De Francesco et al. Dodecyl-TPP Targets Mitochondria in CSCs
These observations pave the way for further exploring the potential of TPP-based
derivatives in cancer therapy. Moreover, TPP-based compounds should be investigated
for their potential to discriminate between “normal” and “malignant” mitochondria,
suggesting that distinct biochemical, and metabolic changes in these organelles could
precede specific normal or pathological phenotypes. Lastly, our data validate the
manipulation of the energetic machinery as useful tool to eradicate CSCs.
Keywords: Tri-Phenyl-Phosphonium (TPP), Cancer Stem Cells (CSCs), mitochondria, cancer therapy, vitamin C,
Doxycycline, cancer metabolism, metabolic plasticity
INTRODUCTION
Intact and enhanced metabolic function are necessary to
support the elevated bioenergetic and biosynthetic demands of
cancer cells toward tumor growth and metastatic dissemination
(1, 2). Not surprisingly, mitochondrially-dependent metabolic
pathways provide an essential biochemical platform for cancer
cells, by extracting energy from several distinct fuels sources (3).
Recently, energetic metabolism and mitochondrial
function have been linked to certain dynamics involved in
the maintenance and propagation of Cancer Stem Cells (CSCs),
which are a distinct cell sub-population, within the tumor mass,
involved in tumor initiation, metastatic spread and resistance
to anti-cancer therapies (3–9). For instance, CSCs show a
peculiar and unique increase in mitochondrial mass, as well as
enhanced mitochondrial biogenesis and higher activation of
mitochondrial protein translation, suggestive of a strict reliance
on mitochondrial function (10–13).
Consistent with these observations, elevated mitochondrial
metabolic function, and OXPHOS have been detected in CSCs,
across multiple tumor types (10–13). Likewise, the fluorescent
mitochondrial dye, MitoTracker, has been used to enrich and
purify CSCs, due to its ability to accumulate in and distinguish
between different cancer cell sub-populations, characterized by
a higher degree of anchorage-independent growth and higher
tumor-initiating capability (10). During asymmetric cell division,
“newly-synthesized” mitochondria are clustered within daughter
cells, that retain stem-like phenotype. In contrast, daughter
cells committed to differentiation, progressively loose stem traits
because they receive older, less-efficient mitochondria. This
observation further supports the idea that the most functionally
viable and undamaged mitochondria, are selected for supporting
stemness traits in cancer cells (14).
Based on these observations, novel pharmacological
approaches aimed at targeting mitochondria in CSCs have
been proposed and successfully applied in pre-clinical and
clinical studies (15–23). For instance, the antibiotic Doxycycline,
which decreases mitochondrial protein translation as an off-
target effect, has been suggested for repurposing in the clinical
management of early breast cancer patients for its ability to
selectively target CSCs (21). In addition, compounds carrying
a Tri-Phenyl-Phosphonium (TPP) moiety, that serves as a
Mitochondria Targeting Signal (MTS), have been shown to elicit
selective inhibitory actions in cancer cells, and CSCs, but not in
normal cells (24).
Nevertheless, certain limitations restrain the use of solely anti-
mitochondrial agents in cancer therapy, as adaptive mechanisms
can be adopted in the tumor mass, to overcome the lack of
mitochondrial function (3, 25). These adaptive mechanisms
include the ability of CSCs to shift from oxidative metabolism
to alternate energetic pathways, in a multi-directional process of
metabolic plasticity driven by both intrinsic and extrinsic factors
within the tumor cells, as well as in the surrounding tumor
stroma or niche (7, 26, 27). Notably, in CSCs the manipulation
of such metabolic flexibility can be advantageous to enhance
therapeutic efficacy (23, 26). For instance, synchronizing CSCs
toward certain metabolic dependencies, thus blocking their
ability to shift among several energetic pathways, may represent
a useful strategy toward CSC eradication (23, 26).
Herein, we provide evidence that the TPP derivative dodecyl-
TPP (d-TPP), acting as a potent inhibitor of mitochondrial
function, selectively and preferentially targets cancer cells and
CSCs. As a proof of concept, we show that pharmacological
strategies based on the combined use of mitochondrial (i.e., d-





Doxycycline, Ascorbic Acid, 2-Deoxy-D-glucose (2-DG),
Berberine Chloride, and Niclosamide were all purchased
from Sigma Aldrich. All compounds were dissolved in
DMSO (Dimethyl Sulfoxide), except Ascorbic Acid and
2-deoxy-D-glucose (2-DG), which were dissolved in cell
culture medium.
Cell Cultures
MCF7 and MDA-MB-231 breast cancer cells were obtained from
the ATCC. Human immortalized fibroblasts (hTERT-BJ1) were
originally purchased from Clontech, Inc. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented
with 10% FBS (fetal bovine serum), 2mM GlutaMAX, and 1%
Pen-Strep in a 37◦C humidified atmosphere containing 5% CO2.
Mammosphere Formation
A single cell suspension of MCF-7 or MDA-MB-231 cells was
prepared using enzymatic (1x Trypsin-EDTA, Sigma Aldrich),
and manual disaggregation (25 gauge needle) (28). Cells were
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then plated at a density of 500 cells/cm2 in mammosphere
medium (DMEM-F12/ B27/EGF(20-ng/ml)/PenStrep) under
non-adherent conditions, in culture dishes coated with (2-
hydroxyethylmethacrylate) (poly-HEMA, Sigma Aldrich), in
the presence of treatments, as required. Cells were grown for
5 days and maintained in a humidified incubator at 37◦C
at an atmospheric pressure in 5% (v/v) carbon dioxide/air
mixture. After 5 days for culture, spheres >50µm were counted
using an eye-piece (graticule), and the percentage of cells
plated which formed spheres was calculated and is referred
to as percentage mammosphere formation. Mammosphere
assays were performed in triplicate and repeated three
times independently.
Seahorse XFe-96 Metabolic Flux Analysis
Extracellular acidification rates (ECAR) and real-time oxygen
consumption rates (OCR) forMCF-7 cells were determined using
the Seahorse Extracellular Flux (XFe-96) analyzer (Seahorse
Bioscience) (11). Briefly, 15,000 MCF-7 cells per well were
seeded into XFe-96 well cell culture plates, and incubated
overnight to allow attachment. Cells were then treated with
increasing concentrations of d-TPP (50–500 nM) for 24 h.
Vehicle alone (DMSO) control cells were processed in parallel.
Then, cells were washed in pre-warmed XF assay media (or
for OCR measurement, XF assay media supplemented with
10mM glucose, 1mMPyruvate, 2mML-glutamine, and adjusted
at 7.4 pH). Cells were then maintained in 175 µL/well of
XF assay media at 37C, in a non-CO2 incubator for 1 h.
During the incubation time, 5 µL of 80mM glucose, 9µM
oligomycin, and 1M 2-deoxyglucose (for ECAR measurement)
or 10µM oligomycin, 9µM FCCP, 10µM Rotenone, 10µM
antimycin A (for OCR measurement), were loaded in XF
assay media into the injection ports in the XFe-96 sensor
cartridge. Data sets was analyzed using XFe-96 software and
afterwards the measurements were normalized by protein
content (via the SRB assay). All experiments were performed
three times independently.
Sulphorhodamine B Assay
Protein content in viable cells was assessed inMCF-7 and hTERT-
BJ1 cells, by using the sulphorhodamine (SRB) assay, based on the
measurement of cellular protein content. After treatment with
d-TPP (50–1µM) for 24, 48, or 72 h, cells were fixed with 10%
trichloroacetic acid (TCA) for 1 h in the cold room, and dried
overnight at room temperature. Then, cells were incubated with
SRB for 15min, washed twice with 1% acetic acid, and air dried
for at least 1 h. Finally, the protein-bound dye was dissolved in
a 10mM Tris pH 8.8 solution and read using a plate reader at
540 nm.
xCELLigence RTCA System (ACEA
Biosciences Inc.)
The xCELLigence RTCA system provides a useful approach for
the real-time monitoring of the biological status of adherent
cells, by measuring their electrical impedance, expressed as a
cell index (CI) value. Five thousand MCF-7 cells were seeded
in a 16-well plate (E-plate). Twenty-four hours after seeding,
cells were treated with vehicle or increasing concentrations of
d-TPP (from 50 to 250 nM) for additional 72 h. Real-time cell-
analysis (RTCA) was performed by measuring the cell-induced
electrical impedance values, which were automatically recorded
every 15min for 96 h. This approach allows the quantification of
the onset and kinetics of the cellular response. Experiments were
repeated three times independently, using quadruplicate samples
for each condition.
Statistical Analysis
Data is represented as the mean ± standard error of the
mean (SEM), taken over ≥3 independent experiments, with
≥3 technical replicates per experiment, unless otherwise stated.
Statistical significance was measured, using the t-test. The p ≤
0.05 was considered to be statistically significant.
RESULTS
We have recently established that compounds carrying a
(TPP) moiety inhibit mitochondrial function and, therefore,
reduce CSC propagation (24). More specifically, using an ATP
(Adenosine Triphosphate) depletion assay as a surrogate marker
of mitochondrial dysfunction, we identified, among 9 TPP-
derivatives subjected to screening, the compound 2-butene-
1,4-bis-TPP (b-TPP), as the most effective in inhibiting CSC
propagation (IC-50 ∼ 500 nM) (24). The TPP moiety, which
acts as a mitochondrial targeting signal (MTS), is chemically
attached to a cargo molecule via a covalent bond. The intrinsic
nature of the cargo molecule and its binding to the TPP structure
may deeply influence the accumulation of the TPP-derivative in
the mitochondria of living cells, thereafter impacting its overall
biological function.
Herein, we characterized the metabolic and biological
properties of dodecyl-TPP (d-TPP), establishing a combination
strategy that efficiently targets the energetic cell machinery of
CSCs to achieve their eradication.
d-TPP Inhibits CSC Propagation
Figure 1A shows the structure of d-TPP, which contains a
long hydrophobic saturated aliphatic chain with 12 carbons,
covalently-linked to a TPPmoiety. Figure 1B shows the structure
of b-TPP, which contains two TPPmoieties. In contrast, note that
d-TPP has only one TPP moiety.
Firstly, we performed the mammosphere formation assay
as a read-out for CSC propagation, in the Estrogen Receptor
(ER)-positive MCF-7 breast cancer cells, treated with increasing
concentration of d-TPP. As shown in Figure 1C, treatment with
d-TPP resulted in an 80% reduction in CSC activity at the highest
concentrations tested (500 nM and 1µM); a slight (20%), but
significant reduction, in mammosphere formation was already
observed at very low concentrations (50 and 100 nM). In a
parallel analysis of CSC activity, d-TPP was more than twice as
potent as b-TPP (Figure 1C). A similar inhibitory trend for CSC
propagation was observed in the triple-negative breast cancer
cells line MDA-MB-231 (Figure 1D).
Our previous study has indicated that certain TPP-derivatives
may interfere with mitochondrial function in cancer cells,
impairing their metabolic activity and ultimately leading to a
reduction in cancer cell viability. Of interest, the actions of certain
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FIGURE 1 | d-TPP dose-dependently inhibits mammosphere formation in both ER(+) and triple-negative cell lines. (A,B) Structures of the TPP derivatives d-TPP
(dodecyl-TPP) and b-TPP (2-butene-1,4-bis-TPP). (C,D) Differential inhibition of the mammosphere-forming activity of MCF-7 and MDA-MB-231 breast CSCs, after
treatment with d-TPP (blue) and b-TPP (orange). Cells were treated for 5 days in mammosphere media with vehicle alone (DMSO) or increasing concentrations of the
drugs (50 nM−1µM). Note that d-TPP is approximately twice as potent as b-TPP in inhibiting mammosphere formation, with an IC-50 of approximately 250 nM. Data
shown are the mean ± SEM of at least three independent experiments performed in triplicate. *p < 0.05; ***p < 0.001 indicates significance, all relative to the
vehicle-alone treated cells.
TPP-compounds are selectively elicited on cancer cells, but not
on normal cells (24). Thereafter, we tested the ability of d-TPP to
decrease cell viability in MCF-7 breast cancer cells treated with
increasing concentrations of d-TPP (from 50 nM to 1µM), over
different period of time (from 24 to 72 h). A similar experimental
approach was used in normal human fibroblasts (hTERT-BJ1). As
shown in Figure 2, d-TPP reducedMCF-7 cell viability in a time-
and dose-dependent manner. The highest concentrations of the
compound (250–500 nM and 1µM), led to early reductions in
cell viability (nearly 30%), which was evident already after 24 h of
treatment. After 72 h of treatment, the reduction in cell viability
was nearly 80% for the highest concentrations (250–500 nM and
1µM) and a slight (nearly 30%) but significant inhibitory action
was detected also at the lowest concentrations (50 and 100 nM).
On the other hand, in hTERT-BJ1 cells only the highest
concentrations of the compound (250–500 nM and 1µM) led to
a reduction in cell viability, whereas the lowest concentrations
(50 and 100 nM) showed little or no toxicity (Figures 2B–F).
These results support the idea that d-TPP could be selectively
used to target cancer cells, rather than normal cells, when used
at low concentrations.
d-TPP Inhibits OXPHOS and Activates
Glycolysis Toward the Acquisition of
Metabolic Inflexibility
In cancer cells, the intrinsic ability to flexibly shift from one
fuel source to another, according to the local availability, is
a pre-requisite for abnormally high proliferation, cell survival,
and metastatic dissemination to distant sites (26, 27, 29). Any
pharmacological or metabolic approach aimed at compromising
this flexibility in the energetic cancer cell machinery will
negatively impact tumor progression [reviewed in (26)].
To understand the effects of d-TPP treatment on cancer
cell metabolism, we performed metabolic flux analysis using
the Seahorse XFe96. In MCF-7 cells, a dramatic reduction in
(OCR) was observed after 24 h of treatment, with increasing
concentrations of d-TPP (Figure 3). Basal mitochondrial
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FIGURE 2 | Effects of d-TPP on cell viability. Evaluation of cell viability using the SBR assay in MCF-7 (A,C,E) and h-TERT BJ1 (B,D,F) cells treated with increasing
concentrations of d-TPP (50 nM−1µM) for 24, 48, and 72 h, as indicated. Data shown are the mean ± SEM of at least three independent experiments performed in
triplicate. *p < 0.05; **p < 0.01; ***p < 0.001 indicates significance, all relative to the vehicle-alone treated cells.
respiration was reduced, with an IC-50 of ∼250 nM (the same
concentration of the d-TPP necessary to halve CSC activity);
likewise, ATP levels were also dose-dependently depleted.
Strikingly, the opposite trend was observed for glycolysis,
which was substantially and dose-dependently increased, as
indicated by the analysis of ECAR (extracellular acidification
rate) in MCF-7 cells treated with d-TPP (Figure 4).
Taken together, these data indicate that d-TPP impairs
mitochondrial function, thereafter compromising the ability to
obtain ATP from oxidative phosphorylation. In order to cope
with this stressful metabolic setting, cancer cells are forced
toward a purely glycolytic phenotype, more strictly depending on
glucose to fulfill their high energetic demands. In this scenario,
the anti-mitochondrial effect elicited by d-TPP treatment serves
as a functional metabolic synchronizer toward an obligated and
inflexible glycolytic dependence.
Using d-TPP in a “Two-Hit” Metabolic
Strategy to Potently Target CSCs
Vulnerabilities
As we previously observed, this scenario of energetic inflexibility
can be further exploited to metabolically weaken CSCs, by
the addition of other metabolic stressors (23, 26). Therefore,
we performed 3D mammosphere assays using d-TPP in
combination with selected glycolysis and OXPHOS inhibitors, of
both synthetic and natural origin, including two FDA approved
drugs, as detailed below.
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FIGURE 3 | Mitochondrial respiration is inhibited in MCF-7 cells treated with d-TPP. The metabolic profile of MCF-7 cells treated with increasing concentrations of
d-TPP (50–500 nM) was assessed using the Seahorse XFe96 analyzer. (A) Representative tracings of metabolic flux. Dose-dependent significant reductions in basal
respiration, maximal respiration, ATP levels, and spare respiratory capacity were observed (B). Data shown are the mean ± SEM of 3 independent experiments
performed in sextuplicate. *p < 0.05; **p < 0.01; ***p < 0.001 indicates significance, all relative to the vehicle-alone treated cells.
This drug combination strategy has been designed as a
“two-hit” scheme, where the first metabolic hit is represented
by d-TPP and the second metabolic hit is represented by
either Vitamin C, 2-deoxy-glucose, Doxycycline, Niclosamide, or
Berberine Chloride.
For this set of experiments, we selected a concentration of d-
TPP equal to 100 nM, which is the dose of the chemical selectively
toxic only to cancer cells, but not normal cells (Figure 2).
Of note, a natural (Vitamin C) as well as a synthetic (2-deoxy-
glucose, 2-DG) glycolysis inhibitor were able to potentiate the
inhibitory effect of d-TPP on CSC activity (Figures 5A,B). In
particular, treatment with Vitamin C inhibited the propagation
of CSCs by >50% at 250µM and >70% at 500µM, when used in
combination with d-TPP (100 nM) (Figure 5A). Previously, we
showed that the IC-50 for Vitamin C is 1mM for MCF-7 CSC
propagation (13). Therefore, treatment with d-TPP confers an
approximate 4-fold increase in CSC sensitivity to Vitamin C.
The inhibitory effect of 2-DG was observed already at the
concentration of 10mM (which conferred a 2-fold increase in
the inhibitory effect of d-TPP alone) and was more dramatic at
20mM (almost completely suppressing CSC activity, with <10%
residual mammosphere formation capability) (Figure 5B).
Next, we used two FDA-approved drugs, namely Doxycycline
and Niclosamide, as well as the natural compound Berberine,
all known to behave as OXPHOS inhibitors (11, 20, 30). This
strategy is based on the assumption that in cancer cells weakened
by d-TPP treatment, an additional metabolic mitochondrial
stressor may help to eradicate the residual CSC population.
As shown in Figure 5C, low doses of the antibiotic
Doxycycline (10µM), which is known to impair mitochondrial
biogenesis and function, were sufficient to double the efficacy of
d-TPP on CSC activity; this effect was potentiated in the presence
of 30µM Doxycyline. Interestingly, the anti-tapeworm drug
Niclosamide, which inhibits OXPHOS, increased the efficacy of
d-TPP on CSC activity by nearly 2-fold at 250 nM and by nearly
3-fold at 500 nM (Figure 5D).
Finally, we used the natural compound and OXPHOS
inhibitor Berberine, the main alkaloid extracted from Coptidis
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FIGURE 4 | Glycolysis is increased in MCF-7 cells treated with d-TPP. The metabolic profile of MCF-7 cells treated with increasing concentrations of d-TPP (50 nM to
500 nM) was assessed using the Seahorse XFe96 analyzer. (A) Representative tracings of metabolic flux. (B) Dose-dependent significant increases in glycolysis and
decreases in glycolytic reserve, as well as glycolytic reserve capacity, were observed. Data shown are the mean ± SEM of three independent experiments performed
in sextuplicate. *p < 0.05; **p < 0.01; ***p < 0.001 indicates significance, all relative to the vehicle-alone treated cells.
rhizoma (Coptis chinensis Franch) and Phellodendri cortex
(Phellodendron amurense Ruprecht), with known anti-malarial,
anti-inflammatory and antibiotic activity (31). At the highest
concentration tested (10µM), Berberine inhibited CSC
formation by >80% thereafter increasing the efficacy of d-TPP
by almost 5-fold, nevertheless Berberine’s action was evident
already at 1µM (Figure 5E).
Taken together, these findings suggest that a mitochondrial-
impairing agent like d-TPP compromises the normal functioning
of the energetic cancer cell machinery, thus significantly
narrowing the possibility to flexibly use alternate fuels and
metabolic pathways. This has a negative impact on CSC biology
and propagation, as well as cancer cell viability and proliferation.
The kinetics of d-TPP action on the proliferation of adherent
MCF-7 cells was independently evaluated using the xCELLigence
system that allows the real-time, label-free, monitoring of cell
health and behavior, by measuring electrical impedance, whose
magnitude is strictly dependent on the number of cells.
As shown in Figure 6, the effects of d-TPP on MCF-7 cells
are dose- and time-dependent, with a trend toward reduced cell
number after 72 h of treatment, even with the lowest dose tested
(50 nM d-TPP). At higher doses (100 nM), a major cytostatic
effect was detected, whereas clear cytotoxicity was observed at the
concentration of 250 nM.
DISCUSSION
In this report, we provide solid evidence to validate the use
of an integrated metabolic strategy to eradicate CSCs. More
specifically, we demonstrate that in breast cancer cells the
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FIGURE 5 | A panel of clinically-approved drugs, natural compounds and synthetic chemicals, interfering with cell metabolism, potentiates d-TPP effects on
mammosphere formation. Evaluation of mammosphere formation in MCF-7 cells cultured in low attachment plates and treated with Vehicle or d-TPP (100 nM), alone
or in combination with the glycolysis inhibitors Ascorbic Acid (250 and 500µM) (A), 2-deoxy-glucose (2-DG) (10 and 20mM) (B); the OXPHOS inhibitors Doxycycline
(10 and 30µM) (C), Niclosamide (250 and 500 nM) (D), and Berberine (1 and 10µM) (E). Data shown are the mean ± SEM of at least three independent experiments
performed in triplicate ***p < 0.001 indicates significance, all relative to the vehicle-alone treated cells.
compound d-TPP, which carries a mitochondria-targeting (TPP)
motif, inhibits mitochondrial function, conferring a dose and
time-dependent reduction in cell viability, as well as inhibiting
the formation of 3D mammospheres, assayed as a read-out
for CSC activity. Quantitatively similar results were obtained
with both ER(+) [MCF7] and Triple Negative [MDA-MB-231]
cell lines.
The analysis of metabolic flux revealed that d-TPP potently
inhibits mitochondrial basal respiration, as well as ATP
production, thereby providing a rational for the reduced
functional capability observed in response to the treatment. As
a consequence, d-TPP-treated breast cancer cells preferentially
exhibit a glycolytic phenotype, which allows them to cope with
the anti-mitochondrial effects elicited by d-TPP. Despite the
acquisition of this compensatory glycolytic phenotype, d-TPP
treatment weakens CSCs, rendering them more sensitive to
the action of a second metabolic inhibitor, as evidenced using
the glycolysis inhibitors Vitamin C and 2-DG, as well as the
OXPHOS inhibitors Doxycycline, Niclosamide, and Berberine.
Thus, functional validation of this approach is evidenced by
the almost complete loss of CSCs activity in MCF-7 cells,
simultaneously treated with d-TPP in the presence of other
energetic inhibitors.
Inter- and intra-tumor heterogeneity is one of themain factors
accounting for tumor progression and therapy failure (32). CSCs
originate and drive such heterogeneity, due to their ability to give
rise to a hierarchically differentiated progeny, which contributes
toward the generation of a full repertoire of cell types within
the tumor mass (33, 34). As a consequence, pharmacological
strategies aimed at identifying, and selectively targeting CSCs
are among the most promising, though challenging, therapeutic
approaches (8, 26, 35, 36). Diverse theories have been proposed
for the explanation of the origin of CSCs. According to the so-
called “metabo-stemness” model, certain metabolic phenotypes
may dictate the stemness properties of tumors, suggesting that
specific metabolic dynamics may drive the de novo acquisition
of stem cell traits in non-cancer or differentiated cancer cells
(37, 38). Likewise, onco-metabolism has been included among
the hallmarks of cancer (39). On the basis of these observations,
it’s not surprising that cancer metabolism has been regarded
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FIGURE 6 | Real-time profiling of cell viability using the xCELLigence system. The xCELLigence system allows for the real-time, label-free, monitoring of cell health,
and behavior, via high frequency measurement of cell-induced electrical impedance. Five-thousand MCF-7 cells were seeded in a 16-well E-plate. Twenty-four hours
after seeding, cells were treated with increasing concentrations of d-TPP (50–250 nM) for further 72 h. (A,C) Representative cell tracings of the impedance profile
indicating the normalized cell index is shown at 48 h (A) and 72 h (C). (B,D) The graphs show cell index values, normalized at the time of d-TPP stimulation, reached
after 48 (B) or 72 h (D) of d-TPP treatment. Data shown are the mean ± SEM of at least three independent experiments performed in triplicate. *p < 0.05; ***p <
0.001 indicates significance, all relative to the vehicle-alone treated cells.
as an opportunity to selectively target CSCs (26, 40). In this
regard, our laboratory and others have demonstrated that CSCs
across diverse tumor types show peculiar metabolic features,
for instance an increased capacity for OXPHOS, elevated
mitochondrial biogenesis, as well as higher mitochondrial mass,
compared to the non-stem or “bulk” cancer cell population
[reviewed in (26)]. Corroborating these findings, cancer cells
with higher telomerase (hTERThigh) activity and therefore higher
immortality features, exhibit an increased mitochondrial mass,
compared to their hTERTlow counterparts (41, 42). Furthermore,
a metabolic rewiring due to mitochondrial dysfunction has
been shown to inhibit cancer cell proliferation, encourage cell
differentiation and halt tumor growth in vivo (43, 44).
Clearly these observations suggest that mitochondrial-
impairing agents could be used to specifically inhibit the CSC
population, paving the way for the identification of chemical
strategies aimed at selectively targeting mitochondria in CSCs
(4, 17, 18, 45, 46). In this regard, the covalent linkage of
a compound to a (TPP) cation represents a well-established
method to deliver probes and imaging agents to mitochondria
(47). TPP+ lipophilic cations may serve as very efficient chemical
“vehicles” to transport small molecules to the mitochondria.
In addition, their chemical synthesis is easily achievable, and
the degree of accumulation in the mitochondria is elevated,
because of the chemical attraction between the positively
charged TPP-cation and the negative membrane potential of
the mitochondrial inner membrane (47). This peculiar chemical
structure would also explain at least some of the biochemical
effects induced by TPP-derivatives, like the dissipation of the
mitochondrial membrane potential, together with the inhibition
of the respiratory chain complexes (48). Recently, we have
demonstrated that the compound 2-butene-1,4-bis-TPP impairs
mitochondrial metabolic function leading to the inhibition of
breast CSC activity (24). The TPP-based compound tested in the
current study, namely dodecyl-TPP, is at least twice as potent
as b-TPP in inhibiting CSC propagation (see Figure 1C). Also,
d-TPP targets the bulk of cancer cells, resulting in a time-
dependent reduction in their viability. According to our data,
it is conceivable to hypothesize that after short time treatment
with d-TPP (24h), cells would have enough metabolic reserves to
cope with the metabolic stress induced by the treatment; whereas
upon stimulation with d-TPP for longer time (48–72 h), no spare
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FIGURE 7 | Schematic diagram showing the proposed “two-hit” metabolic
strategy for eradicating CSCs. Our results suggest that CSCs may be more
efficiently eradicated by using a “two-hit” metabolic strategy based on the use
of a first metabolic inhibitor (i.e., d-TPP), which would weaken CSCs and their
energetic machinery. The starved residual CSC population would be more
sensitive to the detrimental effects of a second metabolic inhibitor (i.e., Vitamin
C, Berberine, Doxycycline, Niclosamide, 2-Deoxy-Glucose). Green: Natural
Compounds; Orange: FDA-approved Drugs; Red: Synthetic drugs.
metabolic fuels would be progressively available for cancer cells
to survive. On the other hand, the compound has limited toxicity
effect on normal fibroblasts. One of the possible explanations of
this effect is that in cancer cells and CSCs, the mitochondrial
membrane potential is higher than in normal cells, and this could
account for the differential effects observed.
As such, TPP-based strategies would therefore be able to
distinguish between “normal” and “malignant” mitochondria,
mainly on the basis of the intrinsic chemical-physical
characteristics of these organelles in health and disease. Of
note, d-TPP treatment caused a shift in energetic metabolism
toward the activation of the glycolytic pathway, which very likely
represents a compensatory response to the anti-mitochondrial
effects elicited by d-TPP.
This metabolic shift has unveiled a strict dependency of cancer
cells on glycolysis after d-TPP treatment, immediately suggesting
the use of a second metabolic (glycolysis or OXPHOS) inhibitor
to further “starve” the residual CSCs population. This two-hit
metabolic strategy had already been implemented and validated
in our previous study (23). This approach is based on the use of a
first metabolic inhibitor (for instance a mitochondrial-impairing
agent) that serves as a first-hit, followed by the use of a
second metabolic inhibitor (for instance a glycolysis or an
OXPHOS inhibitor) that acts as a second-hit (Figure 7). For
example, we have previously demonstrated that: (i) the antibiotic
Doxycycline, acting as a mitochondrial inhibitor, impairs CSCs
activity; (ii) that prolonged treatment with Doxycycline turns
on the glycolytic pathway, in response to the mitochondrial
dysfunction; and (iii) the use of a glycolysis inhibitor, such
as Vitamin C, in combination with Doxycycline completely
eradicates CSCs. These findings indicate that a combination
of Doxycycline plus Vitamin C might conceivably represent a
safe approach for the clinical management of cancer patients.
Indeed, at biologically active concentrations Doxycycline has
a very manageable spectrum of side effects, whereas Vitamin
C has potentially no side effects, being used as additive to
a number of preparations. Adding to this, data coming from
meta-analysis of 21 published studies, as well as pre-clinical
investigations have demonstrated that oral doses of vitamin
C reduce cancer risk, overall mortality and disease-specific
mortality in lung and breast cancer (49–52); furthermore, a
1-week oral administration of ascorbate, performed before cell
inoculation, significantly decreased tumor development in a
lymphoma xenograft model (53).
Clinical validation of these findings, at least for Doxycycline,
has been provided in our recent pilot study, where we enrolled
early breast cancer patients for a short-term (14-day) pre-
operative Doxycycline administration. Notably, the analysis of
post-operative vs. pre-operative breast tumor specimens showed
a selective reduction in the stem markers, namely CD44
and ALDH1, in the patients receiving Doxycycline compared
with controls. This provides exciting clinical evidence that
mitochondrial-targeting strategies may be used to efficiently halt
CSC propagation in cancer patients; nevertheless, additional
studies are still necessary to investigate the action of Doxycycline
together with Vitamin C, in breast cancer patients.
The data herein presented further validate the use of
a metabolic “Two-Hit” approach to manipulate cancer cell
metabolism, turning the metabolic plasticity of CSCs into an
obligate metabolic inflexibility, which would be used to more
efficiently eradicate CSCs. The potential of d-TPP to act as
a safe driver of such a metabolic shift paves the way for
further investigating the role of this compound in cancer
biology and bioenergetics. However, further studies are still
warranted to support the use of TPP-based compounds in
combination with other metabolic inhibitors, as an add-on to
conventional chemotherapy.
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